Evonik Industries

Evonik serves as an end-to-end development partner and solution provider for medical device companies. As a global leader for innovative biomaterials and related application services, Evonik offers an integrated portfolio. This includes RESOMER®, the world’s leading portfolio of bioresorbable polymers, which is for use with implantable medical devices via various processing technologies, including 3D-printing. Another portfolio highlight is Evonik’s clinically proven ENDEXO® surface modification technology, which is based on low-molecular-weight oligomers to enhance the biocompatibility of medical devices such as cardiovascular, neurovascular, and renal applications.


Driven by continuous innovation, Evonik launched the innovative non-animal derived collagen platform VECOLLAN® in 2020. In 2021, Evonik acquired the German biotech company JeNaCell, complementing its offering with biosynthetic cellulose that is ideally suited to medical applications such as wound care, implant materials and scaffolds for tissue engineering.


From its medical device centers of excellence in the U.S., Germany and China, Evonik offers an integrated range of CDMO services. These leverage more than 60 years of market leadership in the design, synthesis, and supply of high-quality polymers to support companies with custom polymer synthesis as well as the development and prototyping of medical device components to match specific customer requirements.

Learn more: https://healthcare.evonik.com/en/medical-devices